BSE Pharma Sector Regulatory Filings — April 18, 2026

NCLT order dated April 15, 2026, directs convening of meetings, providing clear timeline for scheme progression

90.96% secured creditor consent via affidavits demonstrates strong support for composite scheme despite meeting requirement

Equity shareholders meeting scheduled May 27, 2026 at 2:30 PM, key catalyst for potential approval and value unlock

Secured creditors meeting set for May 27, 2026 at 10:00 AM, with high prior consent signaling low risk of rejection

Unsecured creditors meeting for Apollo Healthco on May 27, 2026 at 11:00 AM, advancing integration of subsidiaries

Tribunal clarified prior April 2, 2026 order and fees structure, reducing procedural ambiguity

Modified meeting dates approved (May 26-27, 2026), accelerating path to final sanction

Neutral sentiment (7/10 materiality) on high-consent scheme indicates management conviction in restructuring benefits

No adverse findings in NCLT order, preserving scheme momentum amid no reported insider selling or pledges

Composite scheme covers key entities (Apollo Healthco, Keimed, Apollo Healthtech), potential for operational synergies

Tribunal denied dispensation of secured creditors meeting despite 90.96% consent, signaling stricter oversight

Scheme remains subject to creditor/shareholder approvals at May 26-27 meetings and final NCLT sanction

Clarification of April 2, 2026 order implies prior ambiguities, potential for further legal delays

Secured creditors meeting required despite high consent, risk of any dissenting votes impacting scheme

Meeting for Apollo Healthco on May 27 could face lower consent levels vs. secured (90.96%)

Meetings clustered May 26-27, 2026, tight window may pressure approvals or lead to postponements

Absence of updated period-over-period trends or ratios in filing amid restructuring uncertainty

High 90.96% secured consent positions for smooth May 27, 2026 meetings, unlocking subsidiary synergies

Equity meeting May 27 at 2:30 PM offers binary upside on composite scheme vote

Integration of Apollo Healthco/Keimed/Healthtech could drive cost efficiencies and revenue growth

NCLT's meeting directive post-April 15 order de-risks timeline to final sanction

7/10 materiality undervalued if approvals materialize, potential re-rating

Scheme includes high-growth entities like Apollo Healthco, opportunity for NAV unlock

Watch May 26-27 meetings for positive vote outcomes driving near-term stock momentum

Single filing shows NCLT-facilitated scheme with 90.96% creditor consent, potential early signal of pharma/healthcare M&A wave [IMPLICATION: Consolidation for scale]

Tribunal denial of dispensation despite high consent highlights stricter processes, avg. impact on 1/1 filings [IMPLICATION: Delays but higher approval quality]

3+ meetings scheduled May 26-27 for Apollo entities, building sector event calendar [IMPLICATION: Time-sensitive trading opportunities]

1/1 filings neutral, no bullish/bearish extremes amid procedural updates [IMPLICATION: Stable sector outlook pending outcomes]

Monitor for vote outcomes post-90.96% consent, May 27, 2026 at 10:00 AM

Track Apollo Healthco approval risks, May 27, 2026 at 11:00 AM

Key vote on scheme, potential stock mover, May 27, 2026 at 2:30 PM

Post-meeting approvals, watch for tribunal order in June 2026

No recent trades reported; monitor for buys/sells around May meetings

Await QoQ/YoY trends post-scheme progress, next quarterly filing

Additional scheme filings from peers, period April 18, 2026 onward for consolidation patterns